Search clinical trials for: HPV-16/18 L1 VLP AS04 vaccine

Total 140 results

GlaxoSmithKline

Completed

A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

Infections, Papillomavirus

China
National Institute for Control of Vaccine and Biologicals

Unknown

Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule (HPV-022 PRI)

Human Papillomavirus (HPV) Vaccine

Vietnam
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Infections, Papillomavirus

Japan
GlaxoSmithKline

Completed

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Infections, Papillomavirus

Malaysia
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Infections, Papillomavirus

Belgium, United States
GlaxoSmithKline

Completed

A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Infections, Papillomavirus

Hong Kong
National Cancer Institute (NCI)

Active, not recruiting

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
GlaxoSmithKline

Completed

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

Infections, Papillomavirus

Korea, Republic of
GlaxoSmithKline

Completed

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

Infections, Papillomavirus

India
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

Infections, Papillomavirus

Germany, Spain, France
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

Infections, Papillomavirus
GlaxoSmithKline

Completed

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

Infections, Papillomavirus

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PRISMA)

Cervical Carcinoma | Human Papillomavirus Infection

Costa Rica
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Infections, Papillomavirus

Taiwan, Spain, Germany, Colombia, France, Sweden, Australia, Korea, Republic of, Honduras, Czech Republic, Norway, Panama
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18

Infections, Papillomavirus

Finland, Russian Federation, Denmark, Greece, Netherlands, Estonia
National Cancer Institute (NCI)
Bill and Melinda Gates Foundation

Enrolling by invitation

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (ESCUDDO)

Human Papillomavirus Infection | Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
GlaxoSmithKline

Completed

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

Infections, Papillomavirus

Canada, United States, Brazil
GlaxoSmithKline

Terminated

A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

Human Papillomavirus Infection Leading to Cervical Cancer

Philippines
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Human Papillomavirus (HPV) Infection

Senegal, Tanzania
GlaxoSmithKline

Completed

Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years

Infections, Papillomavirus

Netherlands
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Infections, Papillomavirus

Canada, Denmark, Hungary, Sweden
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Infections, Papillomavirus

United States, Spain, Finland, Germany, Taiwan, Belgium, Philippines, Canada, Australia, United Kingdom, Thailand, Brazil, Italy, Mexico
GlaxoSmithKline

Completed

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Cervical Cancer | Precancerous Condition

Costa Rica
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

HPV Infection | HPV Vaccine | HIV-1-infection

Kenya
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

HIV Infections | Sexually Transmitted Diseases

United States, Puerto Rico
Shanghai Zerun Biotechnology Co.,Ltd
Guangxi Center for Disease Control and Prevention

Completed

A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

Cervical Intraepithelial Neoplasia | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18
University Hospital, Ghent

Completed

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) (HPVXneutra001)

Infection With Human Papillomavirus

Belgium
Kenya Medical Research Institute
University of Washington

Not yet recruiting

Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls

HPV-Related Carcinoma
Jun Zhang
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

Cervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent Infection

China
Jun Zhang
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

Cervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent Infection

China
Shanghai Zerun Biotechnology Co.,Ltd

Unknown

Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females

Human Papillomavirus

China
Merck Sharp & Dohme LLC

Completed

Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)

Papillomavirus Infections | Genital Diseases, Female
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection
Merck Sharp & Dohme LLC

Completed

Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

HPV 16 Infection
GlaxoSmithKline

Completed

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

Cervical Intraepithelial Neoplasia

China
Chulalongkorn University

Unknown

The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease, Stage V

Thailand
GlaxoSmithKline

Completed

Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine

Infections, Papillomavirus

Japan
Shanghai Zerun Biotechnology Co.,Ltd
Guangxi Center for Disease Control and Prevention

Completed

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

Cervical Intraepithelial Neoplasia | Human Papillomavirus | Persistent Infection

China
Prof. Jan Prins

Completed

HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) (VACCAIN-P)

HIV | AIN

Netherlands
Merck Sharp & Dohme LLC

Completed

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Human Papillomavirus Infection
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Cervical Intraepithelial Neoplasia | Papillomavirus Infection

Taiwan, Germany, Colombia, Honduras, Panama
University of North Carolina, Chapel Hill

Completed

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

HIV Infection

United States, Puerto Rico
Medstar Health Research Institute
Merck Sharp & Dohme LLC

Completed

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Cervical Cancer | Warts | Hpv

United States
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Cervical Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) (FUTURE II)

Cervical Cancer | Genital Warts
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Infections, Papillomavirus | Papillomavirus Vaccines

Thailand, Estonia, India, Brazil
Beijing Health Guard Biotechnology, Inc
University of Muhammadiyah Malang Hospital; Dr. M Djamil Hospital, Padang

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Human Papillomavirus Infection

Indonesia
Alessandro Ghelardi

Not yet recruiting

Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 (HOPE9)

Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)

Not yet recruiting

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Human Papillomavirus-Related Carcinoma

United States, Austria

3

Subscribe